附件 99.1

Citius PharmPharmticals Execute達成最終協議，將全資子公司與TenX Keane收購合併，成立上市公司Citius Oncology，Inc.

Citius 製藥公司將獲得Citius Oncology，Inc.6.75億美元的股權，並在交易後保留公開上市的Citius Oncology，Inc.約90%的多數控制權

交易 預計將於2024年上半年完成

美國新澤西州克蘭福德和紐約2023年10月24日電花旗製藥公司(以下簡稱“花旗製藥”或“公司”) (納斯達克股票代碼：CTXR)，一家開發和商業化一流危重護理產品的生物製藥公司與一家上市特殊用途收購公司TenX Keane(“TenX”)(納斯達克：Tenku)今天宣佈，他們已於2023年10月23日簽訂了一項最終協議。對於擬議中的TenX和Citius Pharma的全資腫瘤學子公司 的合併，該子公司將繼續作為一家在納斯達克交易所上市的上市公司。新合併的上市公司將命名為Citius Oncology， Inc.(“Citius Oncology”)。根據合併協議的條款，完成交易後，Citius Pharma將以每股10美元的價格獲得6,750萬股Citius Oncology的股份，並保留約90%的多數股權。這筆交易已獲得兩家公司董事會的批准，預計將於2024年上半年完成。

Citius 腫瘤學概述

Citius腫瘤學將作為開發和商業化新型靶向腫瘤學療法的平臺。該公司正在尋求LYMPHIR的美國食品和藥物管理局(FDA)的批准，作為治療持續性或複發性皮膚T細胞淋巴瘤(CTCL)的孤兒適應症。CTCL是一種罕見的非霍奇金淋巴瘤。管理層估計，LYMPHIR的初始市場目前超過4億美元，正在增長，現有療法無法提供足夠的服務。如果獲得批准，LYMPHIR將成為唯一一種針對CTCL療法的IL-2受體靶向療法，為循環接受多種治療的患者提供了一種新的選擇。強大的知識產權保護 涵蓋孤兒藥物指定、複雜的技術、商業祕密和正在申請的免疫腫瘤學專利，作為檢查點抑制劑的聯合療法 將進一步支持Citius Oncology的競爭地位。

正在為2024年初重新提交生物製品許可證申請(BLA)進行準備工作。如果獲得批准，LYMPHIR最早可能在2024年下半年用於治療CTCL。在更大的市場中創造價值的其他機會包括外周T細胞淋巴瘤的潛在適應症或作為CAR-T和PD-1抑制劑的聯合療法，在美國以外的市場 目前正在進行兩項由研究人員發起的試驗，以探索LYMPHIR作為免疫腫瘤聯合療法的潛力。

這筆交易預計將為Citius Oncology提供更好的公開股票市場準入，從而促進LYMPHIR的商業化 ，並使公司能夠更充分地探索更多創造價值的機會。

Citius Pharma和TENX評論

我們 相信這筆交易將使我們能夠釋放LYMPHIR的價值，並使Citius Pharma穩固地推進我們多樣化的 渠道。這筆交易將使Citius Oncology能夠進入更廣泛的資本市場，如果獲得批准，將更好地支持LYMPHIR的成功商業化，並探索更多潛在的腫瘤靶向療法。我們的多數股權地位和共享服務協議確保Citius Pharma管理團隊將繼續全力參與Citius Oncology的開發和商業化工作。正如之前宣佈的那樣，該公司正在制定向其股東分配Citius Oncology部分股份的計劃。在Citius Pharma，我們打算專注於完成Mino-Lok試驗，並繼續 評估我們的Halo-Lido計劃的下一步行動，“Citius Pharma董事長兼首席執行官Leonard Mazur説。

TenX董事長兼首席執行官袁曉峯表示：“我們非常高興地宣佈與Citius Oncology擬議中的合併。”在與外部顧問一起進行了探索和評估眾多潛在業務合併目標的全面流程後，我們的董事會和管理團隊相信，與Citius Oncology的交易代表着為我們的股東創造實質性價值的最佳機會。如果完成這一業務合併，TenX投資者將擁有該公司的股權，該公司 專注於開發和商業化LYMPHIR，以改善CTCL患者的生活，並 與具有更大潛在市場的其他藥物作為免疫腫瘤療法的組合帶來額外的潛在好處。我們很高興能在Citius Oncology發展的轉折點支持Citius Oncology，併為Citius迅速實現其發展里程碑提供一條途徑。“

擬議的合併協議

根據擬議的協議，TenX將通過合併收購Citius Pharma的全資子公司，新合併的上市公司將命名為Citius Oncology，Inc.。在交易中，Citius Pharma的全資子公司的所有股份將 轉換為獲得Citius Oncology普通股的權利。因此，完成交易後，Citius Pharma將獲得6,750萬股Citius Oncology的普通股，按每股10美元的隱含價值計算，在扣除費用和費用之前，Citius Pharma將獲得Citius Oncology 6.75億美元的股權。作為交易的一部分，Citius Pharma將向Citius Oncology捐贈1,000萬美元現金。Citius Oncology將承擔額外的 1275萬個現有選項。

交易完成時，TenX信託賬户中的任何剩餘現金以及Citius Pharma提供的現金都將捐給Citius腫瘤學，以支持持續運營和計劃中的商業化努力。對來自TenX信託賬户的可用現金和保留的交易收益的引用取決於TenX的公眾股東的任何贖回以及支付交易費用和 費用。

完成交易後，Citius Oncology將根據與Citius Pharma達成的共享服務協議運營，Citius Pharma將按季度向Citius Pharma支付費用，由首席執行官Leonard Mazur、首席財務官Jaime Bartushak和首席醫療官Myron Chuuczman博士領導的Citius Pharma團隊的幾名關鍵成員提供服務。邁倫·霍盧比亞克將擔任Citius Oncology董事會的執行副主席。

這筆交易已得到Citius Pharma和TenX兩家董事會的一致批准，但還需得到TenX股東的批准和其他慣常的成交條件。Citius Pharma作為Citius Oncology普通股的唯一持有人，已經批准了這筆交易。 擬議的業務合併預計將於2024年上半年完成。

交易條款的更詳細描述和業務合併協議的副本將包括在花旗製藥和TenX各自向美國證券交易委員會(“美國證券交易委員會”)提交的最新8-K表格中 。 關於交易，TenX打算向 美國證券交易委員會提交註冊聲明(其中將包含委託書/招股説明書)。

本新聞稿不應構成出售或邀請購買本文所述任何證券的要約， 在任何州或司法管轄區的任何州或司法管轄區內，在根據任何此類州或司法管轄區的證券法進行登記或取得資格之前，不得出售此類證券 。

建議Citius Pharma和TENX股東及其他感興趣的人士閲讀註冊説明書和初步委託書/招股説明書及其任何修正案，以及與業務合併有關的最終委託書/招股説明書，因為這些文件將包含有關Citius Pharma、TENX、Citius Oncology和擬議合併的重要信息。

郵箱：ir@citiuspharma.com

Citius 製藥媒體聯繫人：

攪動通信

格雷格·薩爾斯堡

郵箱：greg@stir-iciations.com

TenX 聯繫人

泰勒 張

郵箱：Target@TenXkeane.com

About Citius Oncology, Inc.

Citius Oncology is a late-stage pharmaceutical company focused on developing and commercializing targeted oncology therapies. Its strategy centers on achieving a market leading position by advancing innovative therapies with reduced development and clinical risks, and leveraging competitive advantages supported by intellectual property and regulatory exclusivity protection. This includes new formulations of previously approved drugs with substantial existing safety and efficacy data or expanded indications for approved therapies.

Citius Oncology’s lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. Management believes the market for LYMPHIR for CTCL, estimated to exceed $400 million, is attractive, growing and underserved by existing treatments. On July 28, 2023, the FDA issued a complete response letter (CRL) in response to the LYMPHIR BLA. The FDA is requiring enhanced product testing and additional controls agreed to with the FDA during the market application review. There were no concerns relating to the safety and efficacy of the clinical data package submitted with the BLA, or the proposed prescribing information. In September 2023, Citius Pharma announced that the FDA has agreed with the plans to address the requirements outlined in the CRL. This guidance has clarified the path forward in completing the necessary activities to support the resubmission of the BLA for LYMPHIR. The BLA resubmission is anticipated in early 2024.

Citius Oncology was founded in August 2021 as Citius Acquisition Corp., a Delaware corporation and wholly owned subsidiary of Citius Pharma and began operations in April 2022. The corporate name was changed to Citius Oncology, Inc. in May 2023.

About Citius Pharmaceuticals, Inc.

Citius Pharma is a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapies. The Company’s diversified pipeline includes two late-stage product candidates. Mino-Lok®, an antibiotic lock solution for the treatment of patients with catheter-related bloodstream infections, is enrolling patients in a Phase 3 Pivotal superiority trial and was granted Fast Track designation by the FDA. Citius Pharma is preparing to resubmit the Biologics License Application for LYMPHIR, a novel IL-2R immunotherapy for an initial indication in CTCL, in early 2024. LYMPHIR received orphan drug designation by the FDA for the treatment of CTCL and PTCL. At the end of March 2023, Citius Pharma completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. For more information, please visit www.citiuspharma.com.

About TenX Keane Acquisition

TenX Keane Acquisition is a blank check company, also commonly referred to as a special purpose acquisition company (SPAC) formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. TenX is led by Xiaofeng Yuan, Chairman and Chief Executive Officer, and Taylor Zhang, Chief Financial Officer, who are growth-oriented executives with a long track record of value creation across industries.

Forward-Looking Statements

This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements regarding the benefits of the transaction, the anticipated timing of the transaction, the products offered by Citius Pharma and Citius Oncology and the markets in which each operates, and Citius Pharma and Citius Oncology’s projected future results. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this document, including, but not limited to: Such statements are made based on our expectations and beliefs concerning future events impacting Citius Pharma. You can identify these statements by the fact that they use words such as “believe,” “anticipate,” “estimate,” “expect,” “plan,” “would,” “should,” and “may” and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: the risk that the transaction may not be completed in a timely manner or at all, which may adversely affect the price of Citius Pharma’s common stock; the risk that the transaction may not be completed by TenX’s business combination deadline and the potential failure to obtain an extension of the business combination deadline if sought by TenX; the failure to satisfy the conditions to the consummation of the transaction, including the adoption of the business combination agreement by the stockholders of TenX; the satisfaction of the minimum trust account amount following redemptions by TenX’s public stockholders; the occurrence of any event, change or other circumstance that could give rise to the termination of the business combination agreement; the effect of the announcement or pendency of the transaction on Citius Pharma’s business relationships, performance, and business generally; risks that the proposed business combination disrupts current plans or operations of Citius Pharma; the outcome of any legal proceedings that may be instituted against Citius Pharma or TenX related to the business combination agreement or the proposed business combination; the ability to maintain the listing of TenX’s securities (which would be Citius Oncology securities) on Nasdaq after the closing of the transaction; after the closing of the transaction, the price of Citius Oncology’s securities may be volatile due to a variety of factors, including changes in the competitive and highly regulated industries in which Citius Oncology will operate, variations in performance across competitors, changes in laws and regulations affecting Citius Oncology’s business and changes in its capital structure; the ability to implement business plans, forecasts, and other expectations after the completion of the proposed business combination, and identify and realize additional opportunities provided by the business combination; the cost and timing of the resubmission of the BLA for LYMPHIR; the FDA may not approve our BLA for LYMPHIR; our need for substantial additional funds; the estimated markets for our product candidates and the acceptance thereof by any market; our ability to commercialize our products if approved by the FDA; our dependence on third-party suppliers; the ability of our product candidates to impact the quality of life of our target patient populations; our ability to successfully undertake and complete clinical and non-clinical trials and the results from those trials for our product candidates; risks relating to the results of research and development activities, including those from existing and new pipeline assets; uncertainties relating to preclinical and clinical testing; the early stage of products under development; market and other conditions; our ability to attract, integrate, and retain key personnel; risks related to our growth strategy; patent and intellectual property matters; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; our ability to procure cGMP commercial-scale supply; government regulation; competition; as well as other risks described in our SEC filings. These risks have been and may be further impacted by Covid-19 and global geopolitical events, such as the war in Ukraine and the Middle East. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our Securities and Exchange Commission (“SEC”) filings which are available on the SEC’s website at www.sec.gov, including in our Annual Report on Form 10-K for the year ended September 30, 2022, filed with the SEC on December 22, 2022 and updated by our subsequent filings with the SEC. These forward-looking statements speak only as of the date hereof, and we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

Citius Pharmaceuticals Investor Contact:

Ilanit Allen

ir@citiuspharma.com

Citius Pharmaceuticals Media Contact:

STiR-communications

Greg Salsburg

Greg@STiR-communications.com

TenX Contact

Taylor Zhang

target@TenXkeane.com